Wall Street Zen Upgrades Prime Medicine (NASDAQ:PRME) to Sell

Key Points

• Wall Street Zen upgraded Prime Medicine (NASDAQ:PRME) from a "strong sell" to a "sell," while the broader analyst consensus remains a Moderate Buy with an average price target of $7.38.
• PRME opened at $3.81, has a market cap of $687.9 million and a negative P/E (-2.82), a 52‑week range of $1.11–$6.94, and its 50‑day SMA ($3.65) sits below the 200‑day SMA ($4.06).
• Institutional ownership is high at 70.37%, with notable activity including AQR boosting its stake by ~1,419% and MIRAE Asset significantly increasing its holdings.

Prime Medicine (NASDAQ:PRME - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research note issued on Sunday.

A number of other analysts have also weighed in on the stock. Oppenheimer assumed coverage on shares of Prime Medicine in a research note on Thursday, March 12th. They set an "outperform" rating and a $11.00 price objective for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Prime Medicine in a research note on Monday, December 29th. Finally, Lifesci Capital upgraded shares of Prime Medicine to a "strong-buy" rating in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $7.38.

Prime Medicine Stock Performance

NASDAQ:PRME opened at $3.81 on Friday. The firm has a market cap of $687.90 million, a P/E ratio of -2.82 and a beta of 2.65. Prime Medicine has a fifty-two week low of $1.11 and a fifty-two week high of $6.94. The firm has a 50-day simple moving average of $3.65 and a two-hundred day simple moving average of $4.06.

Hedge Funds Weigh In On Prime Medicine

A number of institutional investors and hedge funds have recently modified their holdings of PRME. AQR Capital Management LLC boosted its stake in shares of Prime Medicine by 1,419.4% in the 1st quarter. AQR Capital Management LLC now owns 243,795 shares of the company's stock worth $485,000 after buying an additional 227,749 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Prime Medicine in the 1st quarter worth $101,000. Rhumbline Advisers boosted its stake in shares of Prime Medicine by 13.8% in the 1st quarter. Rhumbline Advisers now owns 81,900 shares of the company's stock worth $163,000 after buying an additional 9,944 shares during the last quarter. Creative Planning purchased a new position in shares of Prime Medicine in the 2nd quarter worth $25,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Prime Medicine by 253.4% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 119,856 shares of the company's stock worth $296,000 after buying an additional 85,938 shares during the last quarter. 70.37% of the stock is currently owned by hedge funds and other institutional investors.

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.